All In Biotech

Drug Trial Radar · NCT07834073

Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity

Immunogenicity and Safety of a Single Dose of mRNA COVID-19 Vaccine in Chinese Adults With Hybrid Immunity: a Multicentre, Open-label, Single-arm, Post-marketing Study

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,052

Actual

Start

May 23, 2023

Primary completion

Feb 28, 2024

Study completion Feb 28, 2024

Sponsor

Sponsor type
Research network
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicentre post-marketing cohort study to evaluate the immunogenicity and safety of a single dose of mRNA SARS-CoV-2 vaccine SYS6006 in Chinese adults predominantly with hybrid immunity. A total of 2,052 adults aged 18 years and older who received one dose of SYS6006 were monitored for serious adverse events (SAEs) for 6 months. The first 60 participants comprised an immunogenicity subgroup, with blood samples collected before vaccination and at day 14, month 3, and month 6 post-vaccination to assess humoral and cellular immune responses.

Conditions

  • COVID-19
  • SARS-CoV-2 Infection

Interventions

  • SYS6006Biological

    Lipid nanoparticle (LNP)-encapsulated mRNA SARS-CoV-2 vaccine, 30 μg mRNA/0.3 mL, single intramuscular dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titer (GMT) of neutralizing antibodies in the immunogenicity subgroupTime frame: 14 days after booster immunization
  2. Incidence of serious adverse events (SAEs)Time frame: Within 6 months after the booster administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial Center for Disease Control and Prevention

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.